文献速递冠心病

单次高敏肌钙蛋白I检测对心肌梗死风险分层的价值

Myocardial Infarction Risk Stratification With a Single Measurement of High-Sensitivity Troponin I.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

这项前瞻性多中心观察性研究纳入2212例疑似急性心肌梗死患者,使用两种FDA批准的hs-cTnI检测。结果显示,基线hs-cTnI<5 ng/l可安全识别近一半低危患者(30天急性心梗或死亡敏感性98.6%,NPV 99.6%),而hs-cTnI≥120 ng/l提示高危(阳性预测值≥70%)。

要点

  • 单次hs-cTnI<5 ng/l可识别低危患者,30天急性心梗或死亡敏感性98.6%、NPV 99.6%。
  • hs-cTnI≥120 ng/l提示高危,急性心梗阳性预测值≥70%。
  • 两种FDA批准hs-cTnI检测(Atellica IM TnIH和ADVIA Centaur TNIH)表现一致。

核心结论

  • 基线hs-cTnI与不良事件风险呈连续关系,<5 ng/l可安全识别近一半低危患者,≥120 ng/l识别高危患者。

研究设计与样本

  • 前瞻性、多中心、观察性研究,纳入美国29个中心2212例疑似急性心肌梗死患者,使用Atellica IM TnIH和ADVIA Centaur TNIH检测hs-cTnI。

主要发现

  • 2212例患者中急性心肌梗死发生率为12%。
  • 检测限或定量限对30天急性心梗或死亡的敏感性范围为98.6%至99.6%,NPV范围为99.5%至99.8%。
  • 优化阈值<5 ng/l识别近一半患者为低危,30天急性心梗或死亡敏感性98.6%(95%CI 97.2%至100%),NPV 99.6%(95%CI 99.2%至99.9%)。
  • hs-cTnI≥120 ng/l对急性心肌梗死的阳性预测值≥70%。

关键数值与推荐

  • 低危阈值:hs-cTnI<5 ng/l,30天急性心梗或死亡敏感性98.6%(95%CI 97.2%至100%),NPV 99.6%(95%CI 99.2%至99.9%)。
  • 高危阈值:hs-cTnI≥120 ng/l,急性心梗阳性预测值≥70%。

临床怎么用

  • 疑似急性心梗患者就诊时单次hs-cTnI<5 ng/l可考虑为低危,hs-cTnI≥120 ng/l提示高危需进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited data exist on rapid risk-stratification strategies using the U.S. Food and Drug Administration-cleared high-sensitivity cardiac troponin I (hs-cTnI) assays. OBJECTIVES: This study sought to examine single measurement hs-cTnI to identify patients at low and high risk for acute myocardial infarction (MI). METHODS: This was a prospective, multicenter, observational study of patients with suspected acute MI enrolled across 29 U.S. sites with hs-cTnI measured using the Atellica IM TnIH and ADVIA Centaur TNIH (Siemens Healthineers) assays. To identify low-risk patients, sensitivities and negative predictive values (NPVs) for acute MI and MI or death at 30 days were examined across baseline hs-cTnI concentrations. To identify high-risk patients, positive predictive values and specificities for acute MI were evaluated. RESULTS: Among 2,212 patients, acute MI occurred in 12%. The limits of detection or quantitation resulted in excellent sensitivities (range 98.6% to 99.6%) and NPVs (range 99.5% to 99.8%) for acute MI or death at 30 days across both assays. An optimized threshold of <5 ng/l identified almost one-half of all patients as low risk, with sensitivities of 98.6% (95% confidence interval: 97.2% to 100%) and NPVs of 99.6% (95% confidence interval: 99.2% to 99.9%) for acute MI or death at 30 days across both assays. For high-risk patients, hs-cTnI ≥120 ng/l resulted in positive predictive values for acute MI of ≥70%. CONCLUSIONS: Recognizing the continuous relationship between baseline hs-cTnI and risk for adverse events, using 2 Food and Drug Administration-cleared hs-cTnI assays, an optimized threshold of <5 ng/l safely identified almost one-half of all patients as low risk at presentation, with hs-cTnI ≥120 ng/l identifying high-risk patients.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Sandoval Y, Nowak R, deFilippi CR, et al. Myocardial Infarction Risk Stratification With a Single Measurement of High-Sensitivity Troponin I. J Am Coll Cardiol. 2019. PMID: 31319909. doi:10.1016/j.jacc.2019.05.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。